[1] 孙 颖,滕光菊,常彬霞,等.自身免疫性肝炎采用免疫抑制剂治疗的疗效预测[J].肝脏,2012,17(11):803-807.[2] Di Nuzzo L,Orlando R,Nasca C,et al. Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis [J]. Drug Des Devel Ther,2014,8:555-568.[3] 周琬琦,张海婧,金 晶,等. S1P1受体激动剂FTY720的免疫抑制作用[J].药学学报,2012,47(4) :546-550.[4] 张 雷,朱 彤,孙尔维,等.FTY720作用机制及诱导移植免疫耐受的研究[J].中华外科杂志,2003,41(10):773-777.[5] Boldison J,Chu CJ,Copland DA,et al.Tissue-resident exhausted effector memory CD8+ T cells accumulate in the retina during chronic experimental autoimmune uveoretinitis[J]. J Immunol,2014,192(10):4541-4550.[6] 姜慧卿,张晓岚.肝纤维化的发生机制[J]. 世界华人消化杂志,2000,8(6):687-689.[7] 纪 辉,迟宝荣,张一宁.肝纤维化与肝星状细胞[J]. 吉林大学学报:医学版,2008,34(3):539-541.[8] 高润平,齐晓艳.肝纤维化的发生机制与治疗进展[J]. 世界华人消化杂志,2006,14(23):2263-2269.[9] Matsuda S,Minowa A,Suzuki S,et al. Differential activation of c-Jun NH2-terminal kinase and p38 pathways during FTY720-induced apoptosis of T lymphocytes that is suppressed by the extracellular signal-regulated kinase pathway[J].J Immunol,1999,162(6):3321-3326.[10] Guo R,Ma H, Gao F,et al. Metallothionein alleviates oxidative stress-induced endoplasmic reticulum stress and myocardial dysfunction [J].J Mol Cell Cardiol,2009,47(2) :228-237.[11] Ishitsuka A,Fujine E,Mizutani,et al.YFTY720 and cisplatin synergistically induce the death of cisplatin-resistant melanoma cells through the downregulation of the PI3K pathway and the decrease in epidermal growth factor receptor expression[J].Int J Mol Med,2014,34(4) :1169-1174.[12] Jiang J, Huang X, Wang Y,et al. FTY720 induces cell cycle arrest and apoptosis of rat glomerular mesangial cells [J]. Mol Biol Rep, 2012,39(8) :8243-8250.[13] Essis SA,Laurier-Laurin ME,Pépin ,et al. GluN2B-containing NMDA receptors are upregulated in plasma membranes by the sphingosine-1-phosphate analog FTY720P[J].Brain Res,2015,doi: 10.1016/j.brainres.2015.07.055. [Epub ahead of print].[14] Endo H,Chihara N,Sekiguchi MDK. A case of multiple sclerosis who relapsed early after fingolimod therapy introduced [J]. Rinsho Shinkeigaku, 2015,55(6) :417-420.[15] 郭若涵,白 彬.大型动物实验性肝纤维化及肝纤维化模型的研究进展[J]. 世界华人消化杂志,2013,21(5):421-426.[16] 李政通,李 俊,黄 成,等. CCI4诱导的大鼠肝纤维化模型肝纤维化逆转与MAPK信号通路的研究[J].中国药理学通报,2011,27(6):809-814.[17] 王晓艳,万晓龙,郭晓燕,等.阿罗洛尔、普奈洛尔和卡维地洛对肝硬化大鼠门脉高压症的疗效比较[J].西安交通大学学报:医学版,2015,36(16):730-734.[18] 王 林,李 波,耿智敏,等.索拉菲尼对肝星状细胞活性及活化的影响[J].郑州大学学报:医学版,2014,49(4):501-504.[19] 李彬彬,明 健,陈大贵,等.microRNA在肝纤维化进程中的作用[J].临床肝胆病杂志,2013,29(5):385-388.[20] 陆伦根,李郑红.肝纤维化及肝硬化研究近况[J].临床肝胆病杂志,2013,29(5):321-323. |